FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Pediatric Patients

Article Link: FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Pediatric Patients

NORTHBROOK, Ill., May 27, 2020 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has approved VESIcare LS (solifenacin succinate)…

Source: FDA New Drug Approvals